Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding Damora Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 27 | 25 | −2 |
| Shares | 11.4M | 10.4M | −973.6K (−8.6%) |
| Value | $57.4M | $37.2M | −$20.2M (−35.2%) |
New holders (7)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Advisers, LP | 243,500 | $874.0K | 0.00% |
| Two Sigma Investments, LP | 152,353 | $547.0K | 0.00% |
| Millennium Management LLC | 83,344 | $299.0K | 0.00% |
| State Street Corp | 43,006 | $154.0K | 0.00% |
| Marquette Asset Management, LLC | 24,135 | $87.0K | 0.02% |
| Northern Trust Corp | 19,006 | $68.0K | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 10,400 | $37.0K | 0.00% |
Sold out (9)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Soleus Capital Management, L.P. | 538,152 | $2.72M |
| Maverick Capital LtdSuperinvestorMaverick Capital | 356,309 | $1.80M |
| Asymmetry Capital Management, L.P. | 60,968 | $308.0K |
| Tudor Investment Corp Et Al | 54,100 | $274.0K |
| Blueshift Asset Management, LLC | 25,238 | $128.0K |
| XTX Topco Ltd | 11,018 | $56.0K |
| UBS Group AG | 7,822 | $40.0K |
| Morgan Stanley | 111 | $1.00K |
| Salem Investment Counselors Inc | 5 | $0 |